for delays of generic drugs and biosimilar biological products. Sec. 21022. REMS approval process for subsequent filers. Sec. 21023. Rule of construction. Subpart D—Study on role of Federal assistance in drug development Sec. 21025. Study on role of Federal assistance in drug development. Subpart E—Pharmacy School Outreach Sec. 21031. Pharmacy school outreach. Subpart F—Reports Sec. 21035. Effects of increases in prescription drug price. Part 2—Health Insurance Market Stabilization Sec. 21041. Preserving State option to implement health care marketplaces. Sec. 21042. Providing for additional requirements with respect to the navigator program. Sec. 21043. Federal Exchange outreach and educational activities and annual enrollment targets. Sec. 21044. Short-term limited duration insurance rule prohibition. Sec. 21045. Protection of health insurance coverage in certain Exchanges. Sec. 21046. Sense of Congress relating to the practice of silver loading. Sec. 21047. Consumer outreach, education, and assistance. Sec. 21048. GAO report. Sec. 21049. Report on the effects of website maintenance during open enrollment. Part 3—Budgetary Effects Sec. 21051. Determination of budgetary effects. Subtitle J—Resident Physician Shortage Reduction Sec. 21101. Short title. Sec. 21102. Distribution of additional residency positions. Sec. 21103. Study and report on strategies for increasing diversity. Subtitle K—Direct Medicare Payment for Services Furnished By Physician Assistants Sec. 21201. Direct Medicare payment for services furnished by physician assistants. Subtitle L—Incentivizing Medicaid Expansion Sec. 21301. Short title. Sec. 21302. Increased FMAP for medical assistance to newly eligible individuals. Subtitle M—Medicaid Expansion Parity Sec. 21401. Short title. Sec. 21402. Parity in the timing of the application of higher Medicaid Federal matching rates for ACA newly eligible individuals. Subtitle N—Equality in Medicare and Medicaid Treatment Sec. 21501. Short title. Sec. 21502. Improving access to care for Medicare and